Kodiak Sciences (KOD) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$1.05
- Estimate
- -$1.01
- Surprise
- -3.9%
- Score today
- 4.8/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Kodiak Sciences (KOD) reported a wider loss than forecast — adjusted EPS of -$1.05 against the -$1.01 estimate (a 3.9% shortfall).
Coverage in the report window
- Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-12
- Kodiak Sciences Q3 EPS $(1.05) Misses $(1.01) Estimate — benzinga, 2026-11-12
- Kodiak Sciences to Present at Three Upcoming Investor Conferences — fiscal.ai, 2026-11-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates KOD Sell at 4.8/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -3.9% surprise compares with a +1.5% four-quarter average.
What argues against it
- Concentration risk — Pipeline: tarcocimab, KSI-501 and KSI-101
- Quality below floor (1.7 < 4.0)
- Reward/Risk 0.3:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $108.25
- Price target
- $112.95
- Stop
- $100.67
- Upside to target
- +4.3%
- Reward-to-risk
- 0.3:1
Risk check: RSI 73 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-13 — shown for context, not personalized investment advice.
KOD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $6.80B
- P/E (fwd)
- -31.5
- 52-week range
- $18.05–$112.31
- Off 52-week high
- 3.6%
- RSI (14)
- 73
- Volume vs avg
- 0.65×
- Score today
- 4.8/10